Articles Tagged With:
-
AMA: Ban Direct-to-Consumer Ads
The American Medical Association is concerned the billions of dollars spent on drug and device ads is “driving demand for expensive treatments despite the clinical effectiveness of less costly alternatives” and is “fueling escalating drug prices.”
-
Sildenafil Improves Insulin Sensitivity
Chronic use of sildenafil (Revatio, Viagra) improves insulin sensitivity in prediabetics, according to a new study.
-
Group Calls for Generic Drug Use
The American College of Physicians recommends the use of generic medications when possible.
-
Hospital Consult - December 2015
-
Expanding Safe Prescribing for Metformin
In an era of progressively more expensive interventions for type 2 diabetes, clinicians may wish to re-evaluate the boundaries of safe prescribing for metformin.
-
Potential Benefits of Down Titration Through Inhaled Steroid Discontinuation
The likelihood of serious pneumonia was reduced by 37% in patients who discontinued inhaled corticosteroids vs those who did not.
-
Prostate Cancer Screening: Have Clinicians Been Listening?
Published modeling methods suggest an increase in prostate cancer mortality by omission of universal screening; to date, that has not been the case, but may require a longer window of observation before reaching definitive conclusions.
-
Ultrasound for Trauma
Point-of-care ultrasound is a critical clinical tool that facilitates the early diagnosis of many life-threatening injuries. As with any test, clinicians need to fully appreciate indications and limitations of the diagnostic tool and integrate where advantageous to their practice.
-
Vitamin D: Conclusions From an NIH Conference
Observational studies indicate that low vitamin D status is associated with risk for cardiovascular disease, cancer, diabetes, and other important disorders, but whether this relationship is causal is not yet known, and whether correction of such a causal relationship (if established) will improve outcomes remains to be determined.
-
Good Cardiovascular News from the SGLT2 Inhibitor Class?
The widely celebrated results of a recent landmark trial give at least one physician reasons to pause.